

# Available Exclusively From



## Expanded Bacterial Vaginosis (BV) Testing

MDL has expanded the Bacterial Vaginosis (BV) Panel with Lactobacillus Profiling by qPCR test to allow for a more sensitive and specific determination of BV status, especially when considering the variation among patient vaginal microbial composition and the complex interactions that occur leading to dysbiosis. As BV can be a polymicrobial infectious process involving species that differ among patients with overlapping symptoms with other vaginal disorders, it is critical for an accurate diagnosis to include a comprehensive selection of "pathogenic" bacteria when testing for BV. It also is important to include the detection of Lactobacilli that support vaginal health, whether naturally occurring or introduced by probiotic use, as well as any bacteria that more accurately indicate the transition between a healthy, stable vaginal flora and BV flora.

Test 759 Bacterial Vaginosis (BV) Panel with Lactobacillus Profiling by qPCR Includes

- *Atopobium vaginae*
- Bacterial Vaginosis Associated Bacteria 1 (BVAB1)
- Bacterial Vaginosis Associated Bacteria 2 (BVAB2)
- Bacterial Vaginosis Associated Bacteria 3 (BVAB3)
- *Bacteroides fragilis*
- *Bifidobacterium breve*
- *Gardnerella vaginalis*
- Megasphaera type 1
- Megasphaera type 2
- *Mobiluncus curtisii*
- *Mobiluncus mulieris*
- *Prevotella bivia*
- *Sneathia sanguinegens*
- *Streptococcus anginosus*
- *Lactobacillus crispatus*
- *Lactobacillus gasseri*
- *Lactobacillus jensenii*
- *Lactobacillus iners*
- *Lactobacillus acidophilus*

### Advantages:


- **Includes 14 BV-associated organisms with Lactobacillus Profiling**
- Improved sensitivity and specificity to better correlate symptom presentations with BV status
- Improved resolution and definition of transitional BV.
- MDL's BV Panel accounts for more than 99% of BV infections.
- Atopobium is frequently co-existent with Gardnerella, and both can be resistant to metronidazole.
- Atopobium, Megasphaera and BVAB2 cannot be detected under the microscope.
- Accurate vaginal microbiome assessment with Lactobacillus profiling at no additional charge.
- Lactobacillus profiling indicates the concentration of pathogenic bacteria relative to lactobacillus, enabling tailored treatment decisions based on the pathogen and infection severity.
- Includes *Lactobacillus acidophilus*, a common probiotic bacteria used to treat BV and establish a healthy vaginal microenvironment.

### References:

1. **Diagnosis of Vaginitis** 2022, October 31. "Diagnosis of Vaginitis". [https://www.aetna.com/cpb/medical/data/600\\_699/0643.html](https://www.aetna.com/cpb/medical/data/600_699/0643.html)
2. **Workowski KA, Bachmann LH, Chan PA, et al.** 2021, July 23. "Sexually Transmitted Infections Treatment Guidelines, 2021". <https://www.cdc.gov/mmwr/volumes/70/rr/rr7004a1.htm>



A DIVISION OF



A MEMBER OF GENESIS BIOTECHNOLOGY GROUP

Medical Diagnostic Laboratories  
[www.mdlab.com](http://www.mdlab.com) • 877.269.0090

IH0283 Rel.: 3.2024



**Medical Diagnostic Laboratories L.L.C.**

2439 Kuser Road  
Hamilton, NJ 08690  
Toll Free: 877-269-0090  
Fax: 609-570-1050

[www.mdlab.com](http://www.mdlab.com)

**PATIENT**

MDL # **10100031**

**DOE, BVPANEL N**

**FINAL**

13 JONQUIL CT ADDRESS 2  
PARAMUS, NJ 07653

DOB: 01/01/2000 (Age 24)

14

Gender: Female

Ethnicity: Not provided

Patient ID: N/A

Home #: 732-307-0308

**SPECIMEN**

Type	Source	Collected	Received	Reported
Thin-Prep	Cerv/End	03/13/2024	03/14/2024	N/A

**CLIENT**

NPI: 1710448105

**JOHN DOE MD1**  
**CASSANDRA WOODS, CNM**

Tel: (244) 144-4233

Fax: 452-333-4444

HOUSTON, USA  
TEST  
HOUSTON, GU 23890

**759 Bacterial Vaginosis Panel (with Lactobacillus Profiling) by QPCR**

**Indicative of Abnormal microflora.**

Suggestive of Bacterial Vaginosis.  
Lactobacillus species not detected.



**REPORT HISTORY**

See Bacterial Vaginosis/ Aerobic Vaginitis Trend Report for prior Date of Service

03/14/2024

Bacteria Detected	Indicator	Abundance
749 <i>Sneathia sanguinegens</i>	BV	31.62%
164 BVAB2	BV	29.27%
125 <i>Bacillus fragilis</i>	BV	12.36%
754 <i>Mobiluncus mulieris</i>	BV	12.36%
764 BVAB1	BV	4.53%
165 Megasphaera type 2	BV	2.93%
142 <i>Atopobium vaginae</i>	BV	2.92%
765 BVAB3	BV	1.67%
752 <i>Prevotella bivia</i>	BV	0.88%
748 <i>Streptococcus anginosus</i>	BV	0.88%
165 Megasphaera type 1	BV	0.29%
753 <i>Mobiluncus curtisii</i>	BV	0.29%

**Pathogens Not Detected**

750 *Bifidobacterium breve* \*

132 *Gardnerella vaginalis* \*

\*This test was developed and its performance characteristics determined by the laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

Medical Director, Jing-Jing Yang, M.D.

MDL#: **10100031**

03/25/2024